株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の体外診断用医薬品 (IVD) の提携契約の動向

Global In Vitro Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 355308
出版日 ページ情報 英文 660 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.42円で換算しております。
Back to Top
世界の体外診断用医薬品 (IVD) の提携契約の動向 Global In Vitro Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts
出版日: 2017年09月01日 ページ情報: 英文 660 Pages
概要

当レポートでは、体外診断用医薬品 (IVD) に関連する各種提携契約の動向について調査し、近年締結された各種契約の動向、大規模契約および大手事業者による契約の概要、契約区分・開発ステージ・治療分野・技術タイプ別の一覧などをまとめています。

第1章 イントロダクション

第2章 体外診断用医薬品 (IVD) 関連契約の動向

  • イントロダクション
  • 過去数年の提携動向
  • 提携契約にもっとも活発な事業者
  • 提携契約:契約区分別
  • 提携契約:治療分野別
  • 提携契約の条件
    • 取引総額
    • 契約一時金
    • マイルストーンペイメント
    • ロイヤルティレート

第3章 主要契約

  • イントロダクション
  • 主要契約:契約額別

第4章 提携契約にもっとも活発な事業者

  • イントロダクション
  • 提携契約にもっとも活発な事業者
  • 提携契約にもっとも活発な事業者のプロファイル

第5章 提携契約ディレクトリー

  • イントロダクション
  • 提携契約ディレクトリー

第6章 体外診断用医薬品 (IVD) 関連契約:技術区分別

第7章 提携契約リソースセンター

  • オンラインよる提携
  • 提携イベント
  • 提携契約関連資料

付録1:提携契約 - 企業別 (A-Z)

付録2:提携契約 - 開発ステージ別

  • 創薬
  • 前臨床
  • 第I相
  • 第II相
  • 第III相
  • 申請段階
  • 上市済み
  • 調剤段階

付録3:提携契約 - タイプ別

  • 資産購入
  • 譲渡
  • バイオ医薬品アウトライセンシング
  • 共同開発
  • 共同R&D
  • 共同販売
  • 共同プロモーション
  • CRADA
  • クロスライセンシング
  • 開発
  • 流通販売
  • 株式購入
  • 評価
  • 助成
  • ジョイントベンチャー
  • ライセンシング
  • 訴訟
  • 製造
  • マーケティング
  • 物質移動
  • オプション
  • プロモーション
  • 研究
  • 合意
  • スピンアウト
  • サブライセンス
  • 供給
  • 技術移転
  • 契約解除
  • 保証

付録4:提携契約 - 治療分野別

付録5 -提携区分の定義

Wildwood Venturesについて

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP2120

Global In Vitro Diagnostics Partnering 2010-2017 report provides comprehensive understanding and unprecedented access to the in vitro diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies

Description

The Global In Vitro Diagnostics Partnering 2010-2017 report provides a detailed understanding and analysis of how and why companies enter in vitro diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest In Vitro Diagnostics agreements announced in the life sciences since 2010.

The report takes the reader through a comprehensive review In Vitro Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering In Vitro Diagnostics partnering deals.

The report presents financial deal term values for In Vitro Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the In Vitro Diagnostics partnering field; both the leading deal values and most active In Vitro Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 450 online deal records of actual In Vitro Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of In Vitro Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in In Vitro Diagnostics dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading In Vitro Diagnostics deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in In Vitro Diagnostics dealmaking with a brief summary followed by a comprehensive listing of In Vitro Diagnostics deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of In Vitro Diagnostics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of In Vitro Diagnostics partnering deals signed and announced since Jan 2010. The chapter is organized by specific In Vitro Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by In Vitro Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in In Vitro Diagnostics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of In Vitro Diagnostics technologies and products.

Key benefits

Global In Vitro Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts provides the reader with the following key benefits:

  • In-depth understanding of In Vitro Diagnostics deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of In Vitro Diagnostics agreements with numerous real life case studies
  • Detailed access to actual In Vitro Diagnostics contracts entered into by leading biopharma companies
  • Identify most active In Vitro Diagnostics dealmakers since 2010
  • Insight into terms included in a In Vitro Diagnostics partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

  • Global In Vitro Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to In Vitro Diagnostics trends and structure of deals entered into by leading companies worldwide.

In Vitro Diagnostics Partnering Terms and Agreements includes:

  • Trends in In Vitro Diagnostics dealmaking in the biopharma industry since 2010
  • Analysis of In Vitro Diagnostics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life In Vitro Diagnostics deals
  • Access to In Vitro Diagnostics contract documents
  • Leading In Vitro Diagnostics deals by value since 2010
  • Most active In Vitro Diagnostics dealmakers since 2010

In Global In Vitro Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • The Global In Vitro Diagnostics Partnering 2010-2017: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 450 In Vitro Diagnostics deals.

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Global In Vitro Diagnostics Partnering 2010-2017 report provides the reader with the following key benefits:

  • In-depth understanding of In Vitro Diagnostics deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of In Vitro Diagnostics agreements with numerous real life case studies
  • Detailed access to actual In Vitro Diagnostics contracts entered into by leading biopharma companies
  • Identify most active In Vitro Diagnostics dealmakers since 2010
  • Insight into terms included in a In Vitro Diagnostics partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in In Vitro Diagnostics dealmaking

  • 2.1. Introduction
  • 2.2. In Vitro Diagnostics partnering over the years
  • 2.3. Most active In Vitro Diagnostics dealmakers
  • 2.4. In Vitro Diagnostics partnering by deal type
  • 2.5. In Vitro Diagnostics partnering by therapy area
  • 2.6. Deal terms for In Vitro Diagnostics partnering
    • 2.6.1 In Vitro Diagnostics partnering headline values
    • 2.6.2 In Vitro Diagnostics deal upfront payments7
    • 2.6.3 In Vitro Diagnostics deal milestone payments
    • 2.6.4 In Vitro Diagnostics royalty rates

Chapter 3 - Leading In Vitro Diagnostics deals

  • 3.1. Introduction
  • 3.2. Top In Vitro Diagnostics deals by value

Chapter 4 - Most active In Vitro Diagnostics dealmakers

  • 4.1. Introduction
  • 4.2. Most active In Vitro Diagnostics dealmakers
  • 4.3. Most active In Vitro Diagnostics partnering company profiles

Chapter 5 - In Vitro Diagnostics contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. In Vitro Diagnostics contracts dealmaking directory

Chapter 6 - In Vitro Diagnostics dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - In Vitro Diagnostics deals by company A-Z
  • Appendix 2 - In Vitro Diagnostics deals by stage of development
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation
  • Appendix 3 - In Vitro Diagnostics deals by deal type
  • Asset purchase
  • Assignment
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Litigation
  • Manufacturing
  • Marketing
  • Material transfer
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Termination
  • Warranty
  • Appendix 4 - In Vitro Diagnostics deals by therapy area
  • Appendix 5 -Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering
  • Table of figures
  • Figure 1: In Vitro Diagnostics partnering since 2010
  • Figure 2: Active In Vitro Diagnostics dealmaking activity since 2010
  • Figure 3: In Vitro Diagnostics partnering by deal type since 2010
  • Figure 4: In Vitro Diagnostics partnering by disease type since 2010
  • Figure 5: In Vitro Diagnostics deals with a headline value
  • Figure 6: In Vitro Diagnostics deals with an upfront value
  • Figure 7: In Vitro Diagnostics deals with a milestone value
  • Figure 8: In Vitro Diagnostics deals with a royalty rate value
  • Figure 9: Top In Vitro Diagnostics deals by value since 2010
  • Figure 10: Most active In Vitro Diagnostics dealmakers since 2010
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events
Back to Top